カテゴリー： Market Monitor Global, 世界, 医療/バイオ

CD47（IAP）の世界市場見通し2023年-2029年

◆英語タイトル：CD47 (IAP) Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8396 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月 ◆ページ数：106 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global CD47 (IAP) Market 調査レポートは次の情報を含め、グローバルにおけるのCD47（IAP）市場規模と予測を収録しています。・世界のCD47（IAP）市場：売上、2018年-2023年、2024年-2029年
・世界のCD47（IAP）市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のCD47（IAP）市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「CD47モノクローナル抗体」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

CD47（IAP）のグローバル主要企業は、Gilead、 Innovent Biologics、 Akeso, Inc、 Arch Oncology、 ImmuneOncia Therapeutics、 I-MAB、 Sorrento Therapeutics、 Zai Lab、 ImmuneOnco、 Hengrui、 Beijing Mab-works、 Hanxbio、 ALX Oncology、 Surface Oncology、 TG Therapeutics、 EpicentRxなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、CD47（IAP）のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界のCD47（IAP）市場：タイプ別、2018年-2023年、2024年-2029年
世界のCD47（IAP）市場：タイプ別市場シェア、2022年
・CD47モノクローナル抗体、CD47二重抗体、CD47融合タンパク質

世界のCD47（IAP）市場：用途別、2018年-2023年、2024年-2029年
世界のCD47（IAP）市場：用途別市場シェア、2022年
・固形がん、リンパ腫、その他

世界のCD47（IAP）市場：地域・国別、2018年-2023年、2024年-2029年
世界のCD47（IAP）市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業におけるCD47（IAP）のグローバル売上、2018年-2023年
・主要企業におけるCD47（IAP）のグローバル売上シェア、2022年
・主要企業におけるCD47（IAP）のグローバル販売量、2018年-2023年
・主要企業におけるCD47（IAP）のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Gilead、 Innovent Biologics、 Akeso, Inc、 Arch Oncology、 ImmuneOncia Therapeutics、 I-MAB、 Sorrento Therapeutics、 Zai Lab、 ImmuneOnco、 Hengrui、 Beijing Mab-works、 Hanxbio、 ALX Oncology、 Surface Oncology、 TG Therapeutics、 EpicentRx

*************************************************************

・調査・分析レポートの概要
CD47（IAP）市場の定義
市場セグメント
世界のCD47（IAP）市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のCD47（IAP）市場規模
世界のCD47（IAP）市場規模：2022年 VS 2029年
世界のCD47（IAP）市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのCD47（IAP）の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のCD47（IAP）製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：CD47モノクローナル抗体、CD47二重抗体、CD47融合タンパク質
CD47（IAP）のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：固形がん、リンパ腫、その他
CD47（IAP）の用途別グローバル売上・予測

・地域別市場分析
地域別CD47（IAP）市場規模 2022年と2029年
地域別CD47（IAP）売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Gilead、 Innovent Biologics、 Akeso, Inc、 Arch Oncology、 ImmuneOncia Therapeutics、 I-MAB、 Sorrento Therapeutics、 Zai Lab、 ImmuneOnco、 Hengrui、 Beijing Mab-works、 Hanxbio、 ALX Oncology、 Surface Oncology、 TG Therapeutics、 EpicentRx
...

This report aims to provide a comprehensive presentation of the global market for CD47 (IAP), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CD47 (IAP). This report contains market size and forecasts of CD47 (IAP) in global, including the following market information:
Global CD47 (IAP) Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global CD47 (IAP) market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
CD47 Monoclonal Antibody Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of CD47 (IAP) include Gilead, Innovent Biologics, Akeso, Inc, Arch Oncology, ImmuneOncia Therapeutics, I-MAB, Sorrento Therapeutics, Zai Lab and ImmuneOnco, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the CD47 (IAP) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global CD47 (IAP) Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global CD47 (IAP) Market Segment Percentages, by Type, 2022 (%)
CD47 Monoclonal Antibody
CD47 Double Antibody
CD47 Fusion Protein
Global CD47 (IAP) Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global CD47 (IAP) Market Segment Percentages, by Application, 2022 (%)
Solid Tumor
Lymphoma
Others
Global CD47 (IAP) Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global CD47 (IAP) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies CD47 (IAP) revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies CD47 (IAP) revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gilead
Innovent Biologics
Akeso, Inc
Arch Oncology
ImmuneOncia Therapeutics
I-MAB
Sorrento Therapeutics
Zai Lab
ImmuneOnco
Hengrui
Beijing Mab-works
Hanxbio
ALX Oncology
Surface Oncology
TG Therapeutics
EpicentRx
Outline of Major Chapters:
Chapter 1: Introduces the definition of CD47 (IAP), market overview.
Chapter 2: Global CD47 (IAP) market size in revenue.
Chapter 3: Detailed analysis of CD47 (IAP) company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of CD47 (IAP) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 CD47 (IAP) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global CD47 (IAP) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global CD47 (IAP) Overall Market Size
2.1 Global CD47 (IAP) Market Size: 2022 VS 2029
2.2 Global CD47 (IAP) Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top CD47 (IAP) Players in Global Market
3.2 Top Global CD47 (IAP) Companies Ranked by Revenue
3.3 Global CD47 (IAP) Revenue by Companies
3.4 Top 3 and Top 5 CD47 (IAP) Companies in Global Market, by Revenue in 2022
3.5 Global Companies CD47 (IAP) Product Type
3.6 Tier 1, Tier 2 and Tier 3 CD47 (IAP) Players in Global Market
3.6.1 List of Global Tier 1 CD47 (IAP) Companies
3.6.2 List of Global Tier 2 and Tier 3 CD47 (IAP) Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global CD47 (IAP) Market Size Markets, 2022 & 2029
4.1.2 CD47 Monoclonal Antibody
4.1.3 CD47 Double Antibody
4.1.4 CD47 Fusion Protein
4.2 By Type – Global CD47 (IAP) Revenue & Forecasts
4.2.1 By Type – Global CD47 (IAP) Revenue, 2018-2023
4.2.2 By Type – Global CD47 (IAP) Revenue, 2024-2029
4.2.3 By Type – Global CD47 (IAP) Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global CD47 (IAP) Market Size, 2022 & 2029
5.1.2 Solid Tumor
5.1.3 Lymphoma
5.1.4 Others
5.2 By Application – Global CD47 (IAP) Revenue & Forecasts
5.2.1 By Application – Global CD47 (IAP) Revenue, 2018-2023
5.2.2 By Application – Global CD47 (IAP) Revenue, 2024-2029
5.2.3 By Application – Global CD47 (IAP) Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global CD47 (IAP) Market Size, 2022 & 2029
6.2 By Region – Global CD47 (IAP) Revenue & Forecasts
6.2.1 By Region – Global CD47 (IAP) Revenue, 2018-2023
6.2.2 By Region – Global CD47 (IAP) Revenue, 2024-2029
6.2.3 By Region – Global CD47 (IAP) Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America CD47 (IAP) Revenue, 2018-2029
6.3.2 US CD47 (IAP) Market Size, 2018-2029
6.3.3 Canada CD47 (IAP) Market Size, 2018-2029
6.3.4 Mexico CD47 (IAP) Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe CD47 (IAP) Revenue, 2018-2029
6.4.2 Germany CD47 (IAP) Market Size, 2018-2029
6.4.3 France CD47 (IAP) Market Size, 2018-2029
6.4.4 U.K. CD47 (IAP) Market Size, 2018-2029
6.4.5 Italy CD47 (IAP) Market Size, 2018-2029
6.4.6 Russia CD47 (IAP) Market Size, 2018-2029
6.4.7 Nordic Countries CD47 (IAP) Market Size, 2018-2029
6.4.8 Benelux CD47 (IAP) Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia CD47 (IAP) Revenue, 2018-2029
6.5.2 China CD47 (IAP) Market Size, 2018-2029
6.5.3 Japan CD47 (IAP) Market Size, 2018-2029
6.5.4 South Korea CD47 (IAP) Market Size, 2018-2029
6.5.5 Southeast Asia CD47 (IAP) Market Size, 2018-2029
6.5.6 India CD47 (IAP) Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America CD47 (IAP) Revenue, 2018-2029
6.6.2 Brazil CD47 (IAP) Market Size, 2018-2029
6.6.3 Argentina CD47 (IAP) Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa CD47 (IAP) Revenue, 2018-2029
6.7.2 Turkey CD47 (IAP) Market Size, 2018-2029
6.7.3 Israel CD47 (IAP) Market Size, 2018-2029
6.7.4 Saudi Arabia CD47 (IAP) Market Size, 2018-2029
6.7.5 UAE CD47 (IAP) Market Size, 2018-2029
7 CD47 (IAP) Companies Profiles
7.1 Gilead
7.1.1 Gilead Company Summary
7.1.2 Gilead Business Overview
7.1.3 Gilead CD47 (IAP) Major Product Offerings
7.1.4 Gilead CD47 (IAP) Revenue in Global Market (2018-2023)
7.1.5 Gilead Key News & Latest Developments
7.2 Innovent Biologics
7.2.1 Innovent Biologics Company Summary
7.2.2 Innovent Biologics Business Overview
7.2.3 Innovent Biologics CD47 (IAP) Major Product Offerings
7.2.4 Innovent Biologics CD47 (IAP) Revenue in Global Market (2018-2023)
7.2.5 Innovent Biologics Key News & Latest Developments
7.3 Akeso, Inc
7.3.1 Akeso, Inc Company Summary
7.3.2 Akeso, Inc Business Overview
7.3.3 Akeso, Inc CD47 (IAP) Major Product Offerings
7.3.4 Akeso, Inc CD47 (IAP) Revenue in Global Market (2018-2023)
7.3.5 Akeso, Inc Key News & Latest Developments
7.4 Arch Oncology
7.4.1 Arch Oncology Company Summary
7.4.2 Arch Oncology Business Overview
7.4.3 Arch Oncology CD47 (IAP) Major Product Offerings
7.4.4 Arch Oncology CD47 (IAP) Revenue in Global Market (2018-2023)
7.4.5 Arch Oncology Key News & Latest Developments
7.5 ImmuneOncia Therapeutics
7.5.1 ImmuneOncia Therapeutics Company Summary
7.5.2 ImmuneOncia Therapeutics Business Overview
7.5.3 ImmuneOncia Therapeutics CD47 (IAP) Major Product Offerings
7.5.4 ImmuneOncia Therapeutics CD47 (IAP) Revenue in Global Market (2018-2023)
7.5.5 ImmuneOncia Therapeutics Key News & Latest Developments
7.6 I-MAB
7.6.1 I-MAB Company Summary
7.6.2 I-MAB Business Overview
7.6.3 I-MAB CD47 (IAP) Major Product Offerings
7.6.4 I-MAB CD47 (IAP) Revenue in Global Market (2018-2023)
7.6.5 I-MAB Key News & Latest Developments
7.7 Sorrento Therapeutics
7.7.1 Sorrento Therapeutics Company Summary
7.7.2 Sorrento Therapeutics Business Overview
7.7.3 Sorrento Therapeutics CD47 (IAP) Major Product Offerings
7.7.4 Sorrento Therapeutics CD47 (IAP) Revenue in Global Market (2018-2023)
7.7.5 Sorrento Therapeutics Key News & Latest Developments
7.8 Zai Lab
7.8.1 Zai Lab Company Summary
7.8.2 Zai Lab Business Overview
7.8.3 Zai Lab CD47 (IAP) Major Product Offerings
7.8.4 Zai Lab CD47 (IAP) Revenue in Global Market (2018-2023)
7.8.5 Zai Lab Key News & Latest Developments
7.9 ImmuneOnco
7.9.1 ImmuneOnco Company Summary
7.9.2 ImmuneOnco Business Overview
7.9.3 ImmuneOnco CD47 (IAP) Major Product Offerings
7.9.4 ImmuneOnco CD47 (IAP) Revenue in Global Market (2018-2023)
7.9.5 ImmuneOnco Key News & Latest Developments
7.10 Hengrui
7.10.1 Hengrui Company Summary
7.10.2 Hengrui Business Overview
7.10.3 Hengrui CD47 (IAP) Major Product Offerings
7.10.4 Hengrui CD47 (IAP) Revenue in Global Market (2018-2023)
7.10.5 Hengrui Key News & Latest Developments
7.11 Beijing Mab-works
7.11.1 Beijing Mab-works Company Summary
7.11.2 Beijing Mab-works Business Overview
7.11.3 Beijing Mab-works CD47 (IAP) Major Product Offerings
7.11.4 Beijing Mab-works CD47 (IAP) Revenue in Global Market (2018-2023)
7.11.5 Beijing Mab-works Key News & Latest Developments
7.12 Hanxbio
7.12.1 Hanxbio Company Summary
7.12.2 Hanxbio Business Overview
7.12.3 Hanxbio CD47 (IAP) Major Product Offerings
7.12.4 Hanxbio CD47 (IAP) Revenue in Global Market (2018-2023)
7.12.5 Hanxbio Key News & Latest Developments
7.13 ALX Oncology
7.13.1 ALX Oncology Company Summary
7.13.2 ALX Oncology Business Overview
7.13.3 ALX Oncology CD47 (IAP) Major Product Offerings
7.13.4 ALX Oncology CD47 (IAP) Revenue in Global Market (2018-2023)
7.13.5 ALX Oncology Key News & Latest Developments
7.14 Surface Oncology
7.14.1 Surface Oncology Company Summary
7.14.2 Surface Oncology Business Overview
7.14.3 Surface Oncology CD47 (IAP) Major Product Offerings
7.14.4 Surface Oncology CD47 (IAP) Revenue in Global Market (2018-2023)
7.14.5 Surface Oncology Key News & Latest Developments
7.15 TG Therapeutics
7.15.1 TG Therapeutics Company Summary
7.15.2 TG Therapeutics Business Overview
7.15.3 TG Therapeutics CD47 (IAP) Major Product Offerings
7.15.4 TG Therapeutics CD47 (IAP) Revenue in Global Market (2018-2023)
7.15.5 TG Therapeutics Key News & Latest Developments
7.16 EpicentRx
7.16.1 EpicentRx Company Summary
7.16.2 EpicentRx Business Overview
7.16.3 EpicentRx CD47 (IAP) Major Product Offerings
7.16.4 EpicentRx CD47 (IAP) Revenue in Global Market (2018-2023)
7.16.5 EpicentRx Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. CD47 (IAP) Market Opportunities & Trends in Global Market
Table 2. CD47 (IAP) Market Drivers in Global Market
Table 3. CD47 (IAP) Market Restraints in Global Market
Table 4. Key Players of CD47 (IAP) in Global Market
Table 5. Top CD47 (IAP) Players in Global Market, Ranking by Revenue (2022)
Table 6. Global CD47 (IAP) Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global CD47 (IAP) Revenue Share by Companies, 2018-2023
Table 8. Global Companies CD47 (IAP) Product Type
Table 9. List of Global Tier 1 CD47 (IAP) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 CD47 (IAP) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global CD47 (IAP) Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - CD47 (IAP) Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - CD47 (IAP) Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global CD47 (IAP) Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - CD47 (IAP) Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - CD47 (IAP) Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global CD47 (IAP) Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global CD47 (IAP) Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global CD47 (IAP) Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America CD47 (IAP) Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America CD47 (IAP) Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe CD47 (IAP) Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe CD47 (IAP) Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia CD47 (IAP) Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia CD47 (IAP) Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America CD47 (IAP) Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America CD47 (IAP) Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa CD47 (IAP) Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa CD47 (IAP) Revenue, (US$, Mn), 2024-2029
Table 30. Gilead Company Summary
Table 31. Gilead CD47 (IAP) Product Offerings
Table 32. Gilead CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 33. Gilead Key News & Latest Developments
Table 34. Innovent Biologics Company Summary
Table 35. Innovent Biologics CD47 (IAP) Product Offerings
Table 36. Innovent Biologics CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 37. Innovent Biologics Key News & Latest Developments
Table 38. Akeso, Inc Company Summary
Table 39. Akeso, Inc CD47 (IAP) Product Offerings
Table 40. Akeso, Inc CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 41. Akeso, Inc Key News & Latest Developments
Table 42. Arch Oncology Company Summary
Table 43. Arch Oncology CD47 (IAP) Product Offerings
Table 44. Arch Oncology CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 45. Arch Oncology Key News & Latest Developments
Table 46. ImmuneOncia Therapeutics Company Summary
Table 47. ImmuneOncia Therapeutics CD47 (IAP) Product Offerings
Table 48. ImmuneOncia Therapeutics CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 49. ImmuneOncia Therapeutics Key News & Latest Developments
Table 50. I-MAB Company Summary
Table 51. I-MAB CD47 (IAP) Product Offerings
Table 52. I-MAB CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 53. I-MAB Key News & Latest Developments
Table 54. Sorrento Therapeutics Company Summary
Table 55. Sorrento Therapeutics CD47 (IAP) Product Offerings
Table 56. Sorrento Therapeutics CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 57. Sorrento Therapeutics Key News & Latest Developments
Table 58. Zai Lab Company Summary
Table 59. Zai Lab CD47 (IAP) Product Offerings
Table 60. Zai Lab CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 61. Zai Lab Key News & Latest Developments
Table 62. ImmuneOnco Company Summary
Table 63. ImmuneOnco CD47 (IAP) Product Offerings
Table 64. ImmuneOnco CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 65. ImmuneOnco Key News & Latest Developments
Table 66. Hengrui Company Summary
Table 67. Hengrui CD47 (IAP) Product Offerings
Table 68. Hengrui CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 69. Hengrui Key News & Latest Developments
Table 70. Beijing Mab-works Company Summary
Table 71. Beijing Mab-works CD47 (IAP) Product Offerings
Table 72. Beijing Mab-works CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 73. Beijing Mab-works Key News & Latest Developments
Table 74. Hanxbio Company Summary
Table 75. Hanxbio CD47 (IAP) Product Offerings
Table 76. Hanxbio CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 77. Hanxbio Key News & Latest Developments
Table 78. ALX Oncology Company Summary
Table 79. ALX Oncology CD47 (IAP) Product Offerings
Table 80. ALX Oncology CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 81. ALX Oncology Key News & Latest Developments
Table 82. Surface Oncology Company Summary
Table 83. Surface Oncology CD47 (IAP) Product Offerings
Table 84. Surface Oncology CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 85. Surface Oncology Key News & Latest Developments
Table 86. TG Therapeutics Company Summary
Table 87. TG Therapeutics CD47 (IAP) Product Offerings
Table 88. TG Therapeutics CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 89. TG Therapeutics Key News & Latest Developments
Table 90. EpicentRx Company Summary
Table 91. EpicentRx CD47 (IAP) Product Offerings
Table 92. EpicentRx CD47 (IAP) Revenue (US$, Mn) & (2018-2023)
Table 93. EpicentRx Key News & Latest Developments
List of Figures
Figure 1. CD47 (IAP) Segment by Type in 2022
Figure 2. CD47 (IAP) Segment by Application in 2022
Figure 3. Global CD47 (IAP) Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global CD47 (IAP) Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global CD47 (IAP) Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by CD47 (IAP) Revenue in 2022
Figure 8. By Type - Global CD47 (IAP) Revenue Market Share, 2018-2029
Figure 9. By Application - Global CD47 (IAP) Revenue Market Share, 2018-2029
Figure 10. By Type - Global CD47 (IAP) Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global CD47 (IAP) Revenue Market Share, 2018-2029
Figure 12. By Application - Global CD47 (IAP) Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global CD47 (IAP) Revenue Market Share, 2018-2029
Figure 14. By Region - Global CD47 (IAP) Revenue Market Share, 2018-2029
Figure 15. By Country - North America CD47 (IAP) Revenue Market Share, 2018-2029
Figure 16. US CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 17. Canada CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe CD47 (IAP) Revenue Market Share, 2018-2029
Figure 20. Germany CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 21. France CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 23. Italy CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 24. Russia CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia CD47 (IAP) Revenue Market Share, 2018-2029
Figure 28. China CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 29. Japan CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 32. India CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America CD47 (IAP) Revenue Market Share, 2018-2029
Figure 34. Brazil CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa CD47 (IAP) Revenue Market Share, 2018-2029
Figure 37. Turkey CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 38. Israel CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 40. UAE CD47 (IAP) Revenue, (US$, Mn), 2018-2029
Figure 41. Gilead CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Innovent Biologics CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Akeso, Inc CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Arch Oncology CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. ImmuneOncia Therapeutics CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. I-MAB CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Sorrento Therapeutics CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Zai Lab CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. ImmuneOnco CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Hengrui CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Beijing Mab-works CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Hanxbio CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. ALX Oncology CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Surface Oncology CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. TG Therapeutics CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. EpicentRx CD47 (IAP) Revenue Year Over Year Growth (US$, Mn) & (2018-2023)

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ CD47（IAP）の世界市場見通し2023年-2029年(CD47 (IAP) Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

CD47（IAP）の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp